IMAGE

Supplementary Figure 4.png (28.12 kB)

IMAGE

Supplementary Figure 5.png (28.66 kB)

IMAGE

Supplementary Figure 1.png (82.2 kB)

IMAGE

Supplementary Figure 2.png (52.68 kB)

IMAGE

Supplementary Figure 3.png (52.18 kB)

1/0

5 files

Supplementary Figures – Cost-Effectiveness of Immune checkpoint inhibitors for non-small cell lung cancer as a second line in Taiwan

figure

posted on 2022-02-02, 09:45 authored by Taylor & FrancisTaylor & Francis, Hui Lang, Agnes Chan, John Leung, Chih Chang

Supplementary Figure 1. Cost-Effectiveness of Immune checkpoint inhibitors for non-small cell lung cancer as a second line in Taiwan

Model structure and transitions

Supplementary Figure 2: Cost-Effectiveness of Immune checkpoint inhibitors for non-small cell lung cancer as a second line in Taiwan

Kaplan-Meier and fitted (Log logistic distribution) overall survival and progression-free survival curves for non-small cell lung cancer, Docetaxel.

Supplementary Figure 3: Cost-Effectiveness of Immune checkpoint inhibitors for non-small cell lung cancer as a second line in Taiwan

Kaplan-Meier and fitted (Log-normal distribution)overall survival and progression-free survival curves for non-small cell lung cancer, Nivolumab

Supplementary Figure 4: Cost-Effectiveness of Immune checkpoint inhibitors for non-small cell lung cancer as a second line in Taiwan

Kaplan-Meier and fitted (Log logistic distribution) overall survival and progression-free survival curves for non-small cell lung cancer, Pembrolizumab.

Supplementary Figure 5: Cost-Effectiveness of Immune checkpoint inhibitors for non-small cell lung cancer as a second line in Taiwan

Kaplan-Meier and fitted (Log logistic distribution) overall survival and progression-free survival curves for non-small cell lung cancer, Atezolizumab.